News and Announcements
Kazia Therapeutics CEO featured in the Australian Financial Review
- Published August 20, 2019 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Kazia’s Therapeutics Chief Executive Officer Dr James Garner was featured in a recent article in The Australian Financial Review on the new breed of biotechnology companies.
In the interview, Dr Garner spoke about the importance of networks and collaborations in the biotech industry and how Kazia focuses on structuring and managing the approvals and trial stages of drug development.
The article also talks about the five ongoing trials with Kazia’s lead candidate, GDC-0084 and our recent announcement that leading US cancer treatment centre, Memorial Sloan Kettering (MSK), will use GDC-0084 in a phase I clinical trial for cancer that has spread to the brain (brain metastases).
Read the article here.
Interview with Proactive Investors
Also recently, Dr Garner also discussed the ongoing clinical program with GDC-0084 and the completion of recruitment for Part B of the Cantrixil trial in an interview with Proactive Investors.
In the interview, Dr Garner also discusses:
• Kazia’s strategy with GDC-0084
• How equity market volatility impacts Kazia
• The upcoming milestones and value catalysts for the company
Watch the video interview here.
About Kazia Therapeutics Limited
Kazia Therapeutics Limited (ASX: KZA, NASDAQ: KZIA) is an innovative oncology-focused biotechnology company, based in Sydney, Australia. Our pipeline includes two clinical-stage drug development candidates, and we are working to develop therapies across a range of oncology indications.
Company Updates
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer
In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Backed By Leading Investment Groups and Family Offices
